MannKind Corporation (NASDAQ:MNKD) is trading up modestly at 0.25% having opened trading at $4.01. The stock has a range of $3.97 and $4.09 with volume standing at 873.05K. The development-stage biopharmaceutical company is expected to release findings from its double phase III studies of its inhaled and fast acting insulin dubbed Afrezza. The company’s CEO and founder Al Mann has told investors to expect positive results and he’s indicated that the results when they are released will be followed sharply by a FDA filing for approval.

Only time will tell if Mann’s optimism is shared by the FDA. The company has conducted several studies in the past involving Afrezza and to date the FDA has rejected approval for the drug twice. For now analysts have set a target price of $5.85 and the company is expected to see a 29.06% increase in the EPS this year. Things look even better for 2014 where EPS is expected to rise by 79.60%. With a RSI of 60.47 the stock is not yet overbought and presently it is trading 19.39% above its 50-day simple moving average.

http://gdpinsider.com/galena-biopharma-inc-nasdaqgale-up-6-77-mannkind-corporation-nasdaqmnkd-up-0-21-931.html